- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01592383
Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the objective response rate (complete response [CR] + partial response [PR]) of erlotinib in malignant peritoneal mesothelioma (MPeM) patients who have epidermal growth factor receptor (EGFR) mutations.
SECONDARY OBJECTIVES:
I. To determine the percentage of patients with MPeM who have EGFR mutations. II. To characterize asbestos exposure history and other clinical parameters of patients with MPeM who do or do not have EGFR mutations.
III. To determine the disease control rate (CR + PR + stable disease [SD]) of MPeM patients who have EGFR mutations and are treated with erlotinib.
IV. To determine the progression-free survival (PFS) of MPeM patients who have EGFR mutations and are treated with erlotinib.
V. To determine the median overall survival (OS) of MPeM patients who have EGFR mutations and are treated with erlotinib.
VI. To evaluate toxicity in MPeM patients who have EGFR mutations and are treated with erlotinib.
TERTIARY OBJECTIVES:
I. To characterize the specific EGFR mutations observed in MPeM patients. II. To correlate tumor markers (cancer antigen [CA] 125 and soluble mesothelin-related peptide [SMRP]) with response rate, PFS, and OS in MPeM patients treated with erlotinib.
III. To correlate immunohistochemical staining of EGFR, phosphorylated (p)-EGFR, MET (Metastasis), E-cadherin, vimentin, and CBL (Casitas B-lineage Lymphoma)with EGFR mutational status and, if present, particular EGFR mutation noted.
IV. To correlate immunohistochemical staining of EGFR, p-EGFR, MET, E-cadherin, vimentin, and CBL with response rate, PFS, and OS in MPeM patients treated with erlotinib.
OUTLINE:
Patients receive erlotinib hydrochloride orally (PO) once daily (QD). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up periodically.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637-1470
- University of Chicago Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically- or cytologically-confirmed malignant peritoneal mesothelioma; epithelial, sarcomatoid, biphasic, or well-differentiated papillary subtypes are allowed.
- A tumor block or 10 unstained slides must be available for determining EGFR mutational status; only those patients who have a mutation of the EGFR tyrosine kinase domain will be able to enroll in this study.
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan.
- No prior use of EGFR tyrosine kinase inhibitors or monoclonal antibodies; all other prior treatments are allowed if >= 4 weeks since treatment completed, including chemotherapy (systemic or intraperitoneal), radiation therapy, and/or surgery; there is no limit on the number of previous treatments allowed.
- Life expectancy of greater than 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Leukocytes >= 2,000/mcL.
- Absolute neutrophil count >= 1,500/mcL.
- Platelets >= 100,000/mcL.
- Total bilirubin =< 1.5 X institutional upper limit of normal (ULN).
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional ULN.
- Creatinine =< 2 X institutional ULN OR creatinine clearance >= 30 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.
- The effects of erlotinib on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- Ability to understand and the willingness to sign a written informed screening and treatment consent.
Exclusion Criteria:
- Chemotherapy, radiotherapy, or surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- Patients may not be receiving any other investigational agents.
- Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop. progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib.
- EGFR-mutation negative tumor tissue as determined by sequencing; if an individual tissue test result is inconclusive (unable to be determined), it will be considered negative for study eligibility purposes.
- History of previous malignancy excluding non-melanoma skin lesions and in-situ cervical cancer; patients with other malignancies are eligible if they have been disease free for >= 3 years.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because it is unknown if erlotinib poses a potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with erlotinib, breastfeeding should be discontinued if the mother is treated with erlotinib.
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with erlotinib; in addition, these patients are at increased risk of lethal infections; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.
- Inability to tolerate or absorb an oral medication due to any cause, including but not limited to malabsorption syndromes.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (enzyme inhibitor therapy)
Patients receive erlotinib hydrochloride PO QD.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate
Time Frame: 1 year
|
Objective Response Rate is calculated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS
Time Frame: 1 year
|
Progression free survival (PFS) defined as time from study enrollment until disease progression or death.
|
1 year
|
OS
Time Frame: 1 year
|
Overall survival measured as the time from study enrollment until death.
|
1 year
|
Toxicity
Time Frame: 30 days from the last dose of study drug
|
Toxicity is calculated in terms of adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) criteria version 4.0
|
30 days from the last dose of study drug
|
Disease Control Rate - SD + PR + CR
Time Frame: 1 year
|
Disease Control Rate - SD + PR + CR is calculated as the percentage of patients with either complete response (CR: disappearance of all target lesions), or with partial response (PR: at least 30% decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter of target lesions), or stable disease (SD: neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease of an increase of at least 20% in the sum of the longest diameter of the target lesions taking as reference the smallest sum of longest diameter recorded since the treatment started or the appearance of one or more new lesions).
|
1 year
|
EGFR Mutations Percentage
Time Frame: Baseline
|
EGFR Mutations Percentage is calculated as the percentage of patients who have activating EGFR mutations among all screened patients.
|
Baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Adenoma
- Neoplasms, Mesothelial
- Pleural Neoplasms
- Mesothelioma
- Mesothelioma, Malignant
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
Other Study ID Numbers
- 12-0032
- NCI-2012-00332 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Peritoneal Mesothelioma
-
University of ChicagoNational Cancer Institute (NCI)Active, not recruitingBiphasic Mesothelioma | Epithelioid Mesothelioma | Peritoneal Malignant Mesothelioma | Pleural Biphasic Mesothelioma | Pleural Epithelioid Mesothelioma | Pleural Malignant Mesothelioma | Pleural Sarcomatoid Mesothelioma | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Peritoneal Malignant Mesothelioma | Recurrent Pleural Malignant Mesothelioma | Unresectable Solid Neoplasm | Advanced Pleural Malignant Mesothelioma | Advanced Peritoneal Malignant MesotheliomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingMesothelioma | Mesothelioma, Malignant | Malignant Mesothelioma | Peritoneal Mesothelioma | Malignant Peritoneal MesotheliomaUnited States
-
National Cancer Institute (NCI)TerminatedPrimary Peritoneal Cavity Cancer | Malignant Ascites | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Localized Malignant MesotheliomaUnited States
-
Hospices Civils de LyonRecruitingPeritoneal Malignant MesotheliomaBelgium, Portugal, France, Germany, India, Norway
-
David BartlettNational Cancer Institute (NCI)CompletedPeritoneal Carcinomatosis | Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface | Malignant Peritoneal MesotheliomaUnited States
-
MedImmune LLCActive, not recruitingUnresectable Pleural or Peritoneal Malignant MesotheliomaUnited States, Italy, Spain, United Kingdom, Belgium, Canada, Poland, France, Korea, Republic of, Hungary, Russian Federation, Germany, Australia, South Africa, Netherlands, Romania, Sweden, Israel, Denmark
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingPeritoneal Carcinomatosis | Peritoneal MesotheliomaFrance
-
National Cancer Institute (NCI)CompletedRecurrent Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma | Stage IA Malignant Mesothelioma | Stage IB Malignant Mesothelioma | Stage II Malignant Mesothelioma | Stage III Malignant Mesothelioma | Stage IV Malignant MesotheliomaUnited States
-
National Cancer Institute (NCI)RecruitingPeritoneal Malignant MesotheliomaUnited States
Clinical Trials on erlotinib hydrochloride
-
AVEO Pharmaceuticals, Inc.Biodesix, Inc.TerminatedNon-small Cell Lung CancerKorea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
-
M.D. Anderson Cancer CenterCompletedAdvanced CancersUnited States
-
European Organisation for Research and Treatment...CompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerFrance, Spain, Netherlands, Australia, United Kingdom, Italy, Portugal, Austria
-
University of California, DavisNational Cancer Institute (NCI); Novartis PharmaceuticalsCompletedRecurrent Non-small Cell Lung CancerUnited States
-
Merck Sharp & Dohme LLCCompleted
-
National Cancer Institute (NCI)CompletedCervical Squamous Cell Carcinoma | Recurrent Cervical CancerUnited States
-
Fox Chase Cancer CenterMillennium Pharmaceuticals, Inc.TerminatedNon-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer RecurrentUnited States
-
The Cleveland ClinicUnknownBrain and Central Nervous System TumorsUnited States
-
University Health Network, TorontoNational Cancer Institute (NCI)CompletedHead and Neck CancerCanada
-
National Cancer Institute (NCI)CompletedBreast CancerUnited States